Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML

2d ago, source:

Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML –– Registration-directed ...

Kura Oncology Gets Breakthrough Designation For Leukemia Therapy

2d ago, source:

By Ben Glickman Kura Oncology said Monday it received a breakthrough therapy designation from regulators for ziftomenib, its potential treatment for a ...

Kura Oncology Stock (NASDAQ:KURA), Quotes and News Summary

2mon ago, source: Benzinga.com

Inc. (NYSE: UPS) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter sales results and issued FY24 sales Kura Oncology, Inc. shares are trading ...

FDA grants breakthrough status for Kura Oncology's AML drug candicate

3d ago, source: Investing

SAN DIEGO - Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has awarded Breakthrough Therapy ...

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

1mon ago, source: Nasdaq

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the ...

Kura Oncology Gets FDA Breakthrough Therapy Designation For Ziftomenib In R/R NPM1-Mutant AML

2d ago, source:

Kura Oncology, Inc. (KURA) on Monday announced that it has been granted FDA Breakthrough Therapy Designation for its investigational ...

Kura Oncology Inc

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

FDA grants breakthrough status for Kura Oncology's AML drug candicate

2d ago, source: Investing

SAN DIEGO - Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has awarded Breakthrough Therapy Designation ...

Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML

2d ago, source: Stockhouse

Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a ...

Kura Oncology Inc.

28d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...